Showing results (101-110 of 121) with videos related to

Sort By:
Pageof 13
Molecular Cancer|December 29, 2022
Targeting SOST using a small-molecule compound retards breast cancer bone metastasisLisha Sun, Yixiao Zhang, Guanglei Chen, et al.
Signal Transduction and Targeted Therapy|March 26, 2025
Molecular classification of hormone receptor-positive /HER2-positive breast cancer reveals potential neoadjuvant therapeutic strategiesChao Liu, Lisha Sun, Nan Niu, et al.
Medical Oncology (Northwood, London, England)|November 23, 2011
Clinical implications of ERβ methylation on sporadic breast cancers in Chinese womenLin Zhao, Zhaojin Yu, Yunan Li, et al.
Journal for Immunotherapy of Cancer|October 28, 2020
Checkpoint therapeutic target database (CKTTD): the first comprehensive database for checkpoint targets and their modulators in cancer immunotherapyYixiao Zhang, Yuan Yao, Peng Chen, et al.
Elife|July 28, 2025
Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot studyYu Zhang, Shuo Cao, Nan Niu, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 5, 2017
FSIP1 binds HER2 directly to regulate breast cancer growth and invasivenessTong Liu, Hao Zhang, Li Sun, et al.
Elife|December 22, 2023
Effects of neoadjuvant stereotactic body radiotherapy plus adebrelimab and chemotherapy for triple-negative breast cancer: A pilot studyGuanglei Chen, Xi Gu, Jinqi Xue, et al.
Journal for Immunotherapy of Cancer|February 22, 2024
First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trialShengxiang Ren, Xicheng Wang, Bao-Hui Han, et al.
Annals of Surgical Oncology|June 25, 2025
Surgical and Oncologic Outcomes of Tumescence and Sharp Dissection Versus Electrocautery Dissection in Minimal-Access Nipple-Sparing Mastectomy with Immediate Prosthesis Breast Reconstruction: A Real-World Retrospective Cohort StudyXinyu Ou, Zhihan Liu, Caigang Liu, et al.
The Lancet Regional Health. Western Pacific|October 13, 2025
Neoadjuvant chidamide combined with chemotherapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (MUKDEN 05): a multicentre, single-arm, phase 2 trialJinqi Xue, Huilian Shan, Fang Qiu, et al.
Pageof 13